

## Iowa Medicaid Drug Utilization Review (DUR) Commission

### Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting August 5, 2020

**Location:** Teleconference (Due to COVID-19)  
**Time:** 9:30 a.m. – 1:30 p.m.

#### **WebEx Meeting Link:**

<https://changehealthcare.webex.com/webappng/sites/changehealthcare/meeting/info/166125956166061941?MTID=m089284fd4eabf41014ea282b99fdb4ed>

**Dial In:** 1-844-245-7693

**Meeting Number:** 130 687 9356

#### **Final Agenda**

1. Welcome & Introductions
  - a) Commission Members and Staff
2. Commission Business
  - a) Approval of the Minutes
  - b) March 2020 DUR Recommendation Letter to DHS
  - c) Follow-Up from Previous Meeting(s)
  - d) Commission Recommendations for Retrospective DUR Agenda Topics
  - e) Public Comment Policy – Virtual Meetings
3. IME Pharmacy Update
4. Prevalence Report Summaries
  - a) Amerigroup
  - b) Iowa Total Care
  - c) Fee-for-Service
  - d) Comparative Summary
5. Public Comment\* (*Written Comment Only* - Complete [Speaker Conflict of Interest Disclosure Form](#))
6. Retrospective DUR
  - a) Data Presentation(s)
    - i. Duplicate SNRIs

- ii. Baclofen Utilization
- b) Proposal(s)
  - i. Concurrent Use of Gabapentin and Pregabalin
  - ii. Concurrent Use of an SSRI and SNRI
- 7. Break (10 minutes)
- 8. Prior Authorization
  - a) Acute Migraine Treatments – Initial Review
  - b) Pirfenidone (Esbriet) / Nintedanib (Ofev) – Initial Review
  - c) Adenosine Triphosphate-Citrate Lyase (ACL) Inhibitors – Initial Review
  - d) Peanut Allergen Powder-dnfp (Palforzia) – Initial Review
  - e) Cystic Fibrosis Agents, Oral – Second Review
  - f) Valsartan/ Sacubitril (Entresto) – Second Review
  - g) Novel Oral Anticoagulants – Second Review
  - h) Voxelotor (Oxbryta) – Second Review
  - i) IL-5 Antagonists – Second Review
  - j) Insulin, Pre-Filled Pens – Removal of Prior Authorization – Second Review
- 9. Miscellaneous
  - a) DUR Digest Vol. 32, No. 2 – Second Review
  - b) MedWatch
    - i. [FDA Approves New HIV Treatment for Patients With Limited Treatment Options](#)
    - ii. [FDA Approves Breast Cancer Treatment That Can Be Administered At Home By Health Care Professional](#)
    - iii. [FDA Approves New Therapy for Dravet Syndrome](#)
    - iv. [FDA Approves First Treatment for Adult Onset Still's Disease, a Severe and Rare Disease](#)
    - v. [FDA Approves Drug to Treat Infants and Children with HIV](#)
    - vi. [FDA Approves New Option to Treat Heavy Menstrual Bleeding Associated with Fibroids in Women](#)
    - vii. [FDA Approves New Treatment for a Type of Heart Failure](#)
    - viii. [FDA Approves Additional Treatment for Adults and Adolescents with Hemophilia A or B and Inhibitors](#)
    - ix. [FDA Approves New Treatment for Pediatric Patients with Any Strain of Hepatitis C](#)
    - x. [FDA Approves First Treatment for Group of Progressive Interstitial Lung Diseases](#)

**Next Meeting  
November 4, 2020  
Location TBD**

## 10. Adjournment

\*Due to the teleconference format, ***public comment will be received in written format only*** for Commission review. Data that is to be referenced in the written public comment should be limited to published, peer reviewed literature only. “Data on file” and “articles submitted for review” are not considered published, peer reviewed literature and should not be referenced. Please submit written public comment to [info@iadur.org](mailto:info@iadur.org), including a [completed speaker conflict of interest disclosure form](#) by 4 p.m. CDT August 2, 2020.

**[www.iadur.org](http://www.iadur.org)**

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at [info@iadur.org](mailto:info@iadur.org)

**Next Meeting  
November 4, 2020  
Location TBD**